Litcius/Paper detail

Safety and immunogenicity of a plant-derived recombinant protective antigen (rPA)-based vaccine against Bacillus anthracis: A Phase 1 dose-escalation study in healthy adults

Kristopher Paolino, Jason A. Regules, James E. Moon, Richard C. Ruck, Jason W. Bennett, Shon Remich, Kristin T Mills, Leyi Lin, CaDeidre Washington, Ghariwayne A. Fornillos, Changhong Y. Lindsey, Kristan A. O’Brien, Meng Shi, R. Mark Jones, Brian J. Green, Stephen Tottey, Jessica A. Chichester, Stephen J. Streatfield, Vidadi Yusibov

2022Vaccine20 citationsDOI

Topics & Concepts

ImmunogenicityReactogenicityAnthrax vaccinesBacillus anthracisVaccinationAnthrax toxinMedicineAntigenAdjuvantImmune systemImmunologyImmunizationMicrobiologyVirologyBiologyRecombinant DNAFusion proteinDNA vaccinationGeneticsBacteriaGeneBiochemistryBacillus and Francisella bacterial researchTransgenic Plants and ApplicationsToxin Mechanisms and Immunotoxins
Safety and immunogenicity of a plant-derived recombinant protective antigen (rPA)-based vaccine against Bacillus anthracis: A Phase 1 dose-escalation study in healthy adults | Litcius